Latest News - HighCape Capital

November 12

Quantum-Si Reports Third Quarter 2024 Financial Results

November 07

University of Virginia Researchers Publish New Study on Tropomyosin Proteoforms Showcasing Quantum-Si’s Next-Gen Protein Sequencer™ Platinum®

October 23

Alphina Therapeutics Appoints Veteran Biotech Executive, Nick Galli, as Chief Executive Officer

October 23

Modifi Biosciences Acquired by Merck

October 07

Cybrexa Therapeutics Announces First Patient Dosed with First-in-Class Peptide-Drug Conjugate CBX-12 in Phase 2 Trial in Ovarian Cancer

September 30

SoNE HEALTH and Wellinks Collaboration Connects Patients with Value-Based COPD Care

September 30

Wellinks Acquires Spire Health Creating Industry Leader in Predictive Patient Care for Cardiopulmonary Health

September 18

Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices

September 16

Cybrexa Therapeutics Announces Positive Final Data at ESMO 2024 from Phase 1 Study of Peptide Drug Conjugate CBX-12 in Advanced Solid Tumors

September 06

Elutia Celebrates First Year; Company Thanks Stakeholders and Employees for a Year of Remarkable Growth and Accomplishment

September 05

Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators

September 04

Liberate Bio Integrates Quantum-Si’s Next-Generation Protein Sequencing™ Platform to Enhance Gene Therapy Development

August 27

Quantum-Si Announces New Executive Team Members to Accelerate the Evolution of the Company into a Leading Proteomic Tool Provider

August 08

Wellinks Integrates Virtual Pulmonary Rehabilitation Program at UMass Memorial Health for Massachusetts Residents Living with COPD

August 07

Quantum-Si Reports Second Quarter 2024 Financial Results

August 07

Elutia Announces Second Quarter 2024 Results Launch; Production of EluPro® Underway, Commercial Team Expansion Continues, Financial Position Solidified

August 01

Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds

July 31

Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations

June 25

Industry Leader John Maraganore, Ph.D., Joins Cybrexa Therapeutics as Strategic Advisor

June 17

Elutia Announces $13.26 Million Registered Direct Offering

June 17

Elutia Announces FDA Clearance of EluPro™: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators

May 30

Quantum-Si Appoints Former Bio-Techne President and CEO, Chuck Kummeth, to serve as independent Chairman of the Board of Directors

May 09

Quantum-Si Reports First Quarter 2024 Financial Results

May 09

Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance

April 30

Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time

March 21

Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors

February 29

Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results

February 06

Cybrexa Regains Rights to CBX-12

February 05

Quantum-Si Expands Proteome Coverage and Increases Sequencing Output with New Enhancements to Its Next-Generation Protein Sequencing™ Platform

January 18

Quantum-Si Introduces World’s First Next-Generation Protein Sequencer™ in Japan with Addition of New Distributor

December 18

Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance

December 12

Quantum-Si Expands Global Reach with Addition of New Distributor

November 15

Quantum-Si Adds Distributor ELTA 90 as Demand for Platinum™ Grows

November 13

Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results

November 09

Quantum-Si Reports Third Quarter 2023 Financial Results

November 09

Elutia Completes Divestiture of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

November 08

Quantum-Si Honored as Proteomics Company of the Year by the BioTech Breakthrough Awards

October 16

Modifi Bio Raises Additional $4.3 Million in Seed Funding

September 21

Quantum-Si Appoints Biotech Executive and Entrepreneur, Amir Jafri, to its Board of Directors

September 19

Elutia Announces Private Placement for Proceeds Up to $26 Million

September 18

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

September 06

Aziyo Biologics Rebrands as Elutia to Reflect Strategic Focus on Drug Eluting Biomatrices

August 30

Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures

August 22

Quantum-Si’s Platinum™ Next-Generation Protein Sequencing Instrument Wins Honorable Mention in Fast Company’s 2023 Innovation by Design Awards

August 14

Aziyo Biologics Reports Second Quarter 2023 Financial Results – Transformation Continues to Drug-Eluting Biomatrix Company

August 07

Quantum-Si Reports Second Quarter 2023 Financial Results

July 13

Wellinks Names New CEO Stacie Bratcher

July 13

Aziyo Biologics Announces Voluntary Recall of Viable Bone Matrix Products

July 07

Quantum-Si Debuts New Headquarters in Branford, Connecticut

June 28

Wellinks and Highmark Blue Cross Blue Shield Delaware Reduce Access Barriers for Members with COPD by Offering Virtual Pulmonary Rehabilitation Care

June 21

Quantum-Si Announces the Appointment of Industry Veteran Johan Denecke as Senior Vice President of Operations

May 22

Quantum-Si Appoints Life Sciences and Diagnostics Industry Leader Jack Kenny to its Board of Directors

May 19

Aziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic Envelope- Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices

May 15

Scott Mendel Elected to Quantum-Si Board of Directors

May 11

Quantum-Si Reports First Quarter 2023 Financial Results

May 10

Aziyo Biologics Reports Highest Sales and Gross Profit in Company History – All Four Business Segments Achieved Growth Led by Strong SimpliDerm and CanGaroo Sales

May 02

Quantum-Si Announces the Appointment of Jeff Keyes as Chief Financial Officer

April 24

Quantum-Si Bolsters Executive Leadership Team with Four Key Appointments

April 20

Aziyo Biologics and LeMaitre Vascular Partner for the Distribution of Aziyo’s Cardiovascular Portfolio

April 12

Cybrexa Appoints Jaya Gautam as Senior Vice President of Technical Operations

March 22

Aziyo Biologics Reports Record Full Year 2022 Revenues

March 22

Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction

March 20

Aziyo Biologics Provides Update on FDA Submission for CanGaroo® RM Antibacterial Envelope

March 06

Quantum-Si Reports Fourth Quarter and Fiscal Year 2022 Financial Results

February 01

Cybrexa Strengthens Drug Development Capabilities with the Addition of Laurie Kenvin to the Company’s Leadership Team and Nick Saccomano to the SAB

January 31

Modifi Bio recognized by Senator Chris Murphy as “Innovator of the Month”

January 09

Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum™ Next-Generation Protein Sequence Platform Output

January 09

Quantum-Si Begins Commercial Shipments of the Platinum™ Protein Sequencing System and Provides Business Updates at the 41st Annual J.P. Morgan Healthcare Conference

January 09

Quantum-Si and Aviva Systems Biology Partner to Co-Develop Sample Preparation Kits for Protein Sequencing

January 09

Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results

December 15

Cybrexa Therapeutics Announces the Appointment of Michael N. Needle, MD, as Senior Vice President and Chief Medical Officer

December 13

Dr. Ranjit Bindra named 2022 BioCT Entrepreneur of the Year by BioCT

December 08

Quantum-Si Joins Human Proteome Organization (HUPO) Industrial Advisory Board

December 01

Aziyo Biologics, Inc. Announces Pricing of $11.2 Million Public Offering of Common Stock

November 14

Aziyo Biologics Reports Strong Third Quarter 2022 Revenue; Positive meeting with FDA provides clarity for CanGaroo® RM clearance

November 09

Wellinks is excited to announce the final results of ASPIRE – a clinical trial conducted with the COPD Foundation

November 07

Quantum-Si Reports Third Quarter 2022 Financial Results

November 01

Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan

October 25

Modifi Bio Receives $2.4 Million Award from National Cancer Institute to Advance Innovative Precision Oncology Platform

October 24

Aziyo Biologics Appoints Seasoned Healthcare Executive, David Colpman, to Board of Directors; Industry veteran brings more than 25 years of healthcare business development and transaction experience

October 13

Quantum-Si’s Next-Generation Single-Molecule Protein Sequencing Technology Published in Science, Signaling New Era of Life Science and Biomedical Research

October 11

Aziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key Markets; Senior team enhanced to advance Aziyo’s commercial and financial objectives

October 04

Quantum-Si Appoints Jeff Hawkins as Chief Executive Officer

August 26

Aziyo Biologics Appoints Michelle LeRoux Williams, Ph.D as Chief Scientific Officer; Renown Pioneer in Regenerative Medicine to Lead Company’s Pipeline Development Initiatives

August 11

Aziyo Biologics Announces Second Quarter 2022 Financial Results and Recent Business Achievements, Including Robust Revenue Growth and Strengthened Balance Sheet

August 10

Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings

August 09

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

August 08

Quantum-Si Reports Second Quarter 2022 Financial Results

July 28

Science Publication First to Describe Modifi Bio’s Novel Approach to Fight Cancer Cells with DNA Modification

June 23

Can Virtual Care Reduce COPD Readmissions? Hartford HealthCare and Wellinks Launch the POWER Study to Measure Impact

June 22

Quantum-Si Set to Join the Russell 2000® Index

June 21

Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO

June 16

Quantum-Si Appoints Vikram Bajaj, Ph.D., to Board of Directors

June 01

Quantum-Si Highlights Technology Advancements at the VIB Next-Generation Protein Analysis and Detection Conference

May 09

Quantum-Si Appoints Patrick Schneider as President and Chief Operating Officer

May 09

Quantum-Si Reports First Quarter 2022 Financial Results

May 09

Aziyo Biologics Provides Business Update and Reports First Quarter 2022 Financial Results

April 20

Wellinks Names Dr. Abi Sundaramoorthy as Chief Medical Officer

April 04

Aziyo Announces FDA 510 (k) Submission of CanGaroo RM, It’s Next Generation Biomaterial Envelope Enhanced with Antibiotics

March 03

Aziyo Biologics Reports Fourth Quarter and Full Year 2021 Financial Results

February 28

Quantum-Si Reports Fourth Quarter and Fiscal Year 2021 Financial Results

February 14

Quantum-Si Announces Dr. Jonathan Rothberg as Interim CEO

January 05

COPD Foundation and Wellinks Collaborate to Evaluate Integrated Virtual COPD Management Solution

January 04

Quantum-Si Signs Lease for New Headquarters in New Haven

December 14

Quantum-Si Added to the Nasdaq Biotechnology Index

December 08

Aziyo Biologics Announces Closing of $14.0 Million Private Placement

November 10

Quantum-Si Reports Third Quarter 2021 Financial Results

November 09

Quantum-Si Acquires Majelac Technologies to Strengthen Chip Supply Chain

November 09

Aziyo Biologics Reports Third Quarter 2021 Financial Results

November 02

Wellinks Announces $25M in New Funding to Expand First Integrated Virtual COPD Management Solution to More Patients

October 26

Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting

October 25

Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results

October 19

Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform

August 31

Aziyo Biologics Appoints Peter G. Edwards as General Counsel

August 16

Quantum-Si Reports Second Quarter 2021 Financial Results

August 09

Aziyo Biologics Reports Second Quarter 2021 Financial Results

July 23

Quantum-Si Signs Lease for Product Development and Operations Facility in San Diego Biotechnology Hub

June 08

Cybrexa Therapeutics Announces Publication of Peer-Reviewed Article in NAR Cancer

May 20

Cybrexa Therapeutics Appoints Stephen Basso as Chief Financial Officer

May 10

Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors

April 29

Quantum-Si Appoints Dr. Michael Mina as Chief Medical Advisor

April 22

Quantum-Si Announces Appointment of Claudia Napal Drayton as Chief Financial Officer

March 23

Cybrexa Therapeutics Receives Green Light from FDA on Investigational New Drug Application for CBX-12 (alphalex™-exatecan)

March 10

Cybrexa Therapeutics Closes $25 Million Series B Financing

March 08

Cybrexa Therapeutics Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop CBX-12 (alphalex™- exatecan)

March 01

Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

February 18

CNBC Interview: Inventor Dr. Rothberg on Quantum-Si SPAC deal

February 18

Quantum-Si, a Pioneer in Semiconductor Chip-Based Proteomics, to Combine with HighCape Capital Acquisition Corp.

February 17

Aziyo Biologics Announces First Patient Enrolled in HEAL Study

January 28

Cybrexa Therapeutics Reports Positive Results from GLP Toxicology Study of Lead Candidate CBX-12 (alphalex™-exatecan)

January 28

Aziyo Biologics Announces Updated CanGaroo® Envelope Label in European Markets to Allow for Hydration in an Antibiotic Solution

January 25

21 New “Kids” on the Block: The Most Recent Entrants into the Greater New Haven Biotech Hub

January 14

Wellinks Announces Initiation of IRB Approved Study of Digital Health Solution for COPD

January 12

Surgalign Holdings Announce the Commercial Launch of ViBone® Moldable and the First Clinical Implantation

December 15

Athena Therapeutics announces initial financing from Highcape Capital and Connecticut Innovations

November 19

Aziyo Biologics Reports Third Quarter 2020 Financial Results

November 17

Aziyo Biologics to Participate in the Piper 32nd Annual Virtual Healthcare Conference

November 16

Surgalign Holdings and Aziyo Biologics Announce Expanded Distribution Agreement

November 12

Aziyo Biologics Awarded Breakthrough Technology Contract with Premier Inc.

November 05

Aziyo Biologics to Report Third Quarter 2020 Financial Results on Thursday, November 19, 2020

October 23

HighCape Capital Acquisition Corp. Announces the Separate Trading of its Class A Common Stock and Warrants, Commencing on or about October 26, 2020

October 07

Aziyo Biologics Announces Pricing of Initial Public Offering

September 28

Aziyo Biologics Announces Appointment of Chief Financial Officer

September 21

Aziyo Biologics Announces New Appointments to Board of Directors

September 09

HighCape Capital Acquisition Corp. Announces Closing of $115 Million Initial Public Offering

September 03

HighCape Capital Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering

July 23

Wellinks has been awarded 2020 Venture of the Year from the CT Entrepreneur Awards

July 09

TELA Bio Announces Interim Analysis from BRAVO Study of OviTex® for Ventral Hernia Repair

June 30

TELA Bio Announces Closing of Public Offering of Common Stock

June 29

Aziyo Biologics Announces Launch of OsteGro® V

June 25

TELA Bio Announces Pricing of Public Offering of Common Stock

June 23

TELA Bio Announces Proposed Public Offering of Common Stock

June 15

TELA Bio, Inc. Announces Poster Presentations at the 2020 Minimally Invasive Surgery Symposium (MISS)

April 23

TELA Bio Announces Changes to its Board of Directors

January 08

Convexity Scientific Wellinks Announcement Convexity Activity

November 13

TELA Bio Appoints Federica O’Brien to Board of Directors

November 12

TELA Bio Announces Closing of Initial Public Offering of Common Stock

November 07

TELA Bio Announces Pricing of Initial Public Offering of Common Stock

October 25

Baxter International Acquires HighCape Capital Portfolio Company Cheetah Medical

October 16

TELA Bio readies IPO

September 27

Convexity Scientific raises $4m Series B for Flyp nebulizer

September 10

Baxter CEO Discussing Cheetah Acquisition

September 10

BAXTER ANNOUNCES ACQUISITION OF CHEETAH MEDICAL TO EXPAND SPECIALIZED PATIENT MONITORING PORTFOLIO

August 13

ZIP SURGICAL SKIN CLOSURE DEMONSTRATES SUPERIOR HEALTH ECONOMICS AND CLINICAL OUTCOMES COMPARED TO SURGICAL STAPLES IN TWO RECENTLY PUBLISHED CLINICAL STUDIES

August 08

Aziyo Biologics® Announces Exclusive Agreement with Medtronic® to Distribute FiberCel®

June 13

TELA Bio® to Participate in JMP Securities Life Sciences Conference

May 22

FRESH STUDY RESULTS DEMONSTRATES FLUID RESPONSIVENESS IS DYNAMIC DURING 72-HOUR SEPSIS MONITORING WINDOW

May 21

ZIPLINE MEDICAL SELECTED AS 2019 RED HERRING TOP 100 NORTH AMERICA WINNER

May 20

CHEETAH MEDICAL SHOWCASES FLUID MANAGEMENT EDUCATION WITH VIRTUAL TRAINER APP AT THE 2019 NATIONAL TEACHING INSTITUTE & CRITICAL CARE EXPOSITION

May 08

Aziyo Biologics and Boston Scientific Corporation Enter U.S. Sales Agent Agreement for CanGaroo® Envelope

April 25

TELA Bio® Appoints Kurt Azarbarzin Chairman of Board of Directors

April 18

TELA Bio® Announces 510(k) Clearance for Restella™ Reconstructive BioScaffolds for Reconstructive Surgery

April 10

Aziyo Announces Publication of RECON Study of Pericardial Reconstruction Using ProxiCor

April 08

TELA Bio® to Present at 18th Annual Needham Healthcare Conference

March 25

CHEETAH MEDICAL PARTNERS WITH SEPSIS ALLIANCE TO SUPPORT HEALTHCARE PROVIDER EDUCATION ON SEPSIS – THE THIRD LEADING CAUSE OF DEATH IN THE UNITED STATES

March 21

ZIPLINE MEDICAL ANNOUNCES NEW EMERGENCY DEPARTMENT STUDY SHOWING SIGNIFICANT TIME AND COST SAVINGS, AND SUPERIOR PATIENT SATISFACTION, WITH LACERATION CLOSURE USING ZIP® SURGICAL SKIN CLOSURE

March 19

FRESH STUDY RESULTS SHOW PASSIVE LEG RAISE MAY PREDICT CARDIAC DYSFUNCTION IN SEPTIC SHOCK PATIENTS

March 14

Cheetah Medical Announces Successful Completion of Key Sepsis Clinical Trial

February 14

Cheetah Medical Partners with SWC Funding LLC to Advance Commercial Operations

January 24

TELA Bio Announces First Patient in Europe Treated with OviTex® Reinforced BioScaffolds

January 10

TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance

January 02

Nora Brennan Joins TELA Bio® as Chief Financial Officer

November 29

Aziyo’s CanGaroo Envelope Cleared for Expanded Use with Neurostimulator Devices

November 16

ZipLine Medical Announces Publication of Two Clinical Studies Demonstrating Superior Infection Protection and 22 Percent Reduction in Procedure Time with Zip Surgical Skin Closure

November 06

TELA Bio® Appoints Kurt Azarbarzin to Board of Directors

September 11

TELA Bio® Announces Publication of Case Series Evaluating OviTex® Reinforced BioScaffolds in Hiatal and Inguinal Hernia Repair

August 03

RTI Surgical® and Aziyo® Biologics Announce Exclusive Agreement to Distribute ViBone® for Spine and Other Orthopedic Procedures

June 22

ZipLine Medical Closes $9 Million Growth Financing Led by Existing Investor MVM Partners LLP

June 14

Cheetah Medical’s French Distributor SEBAC SA to Supply Starling SV Monitoring Systems to Paris’ Public Hospital System

June 04

Ronald Lloyd Announced as New President and CEO of Aziyo Biologics

April 03

Improving Cardiology Care: BIOTRONIK US to Distribute Aziyo ECM Envelopes

March 26

TELA Bio Announces Investment Agreement with ProMedica Innovations Venture Fund

March 20

ONGOING ASSESSMENT OF FLUID RESPONSIVENESS IMPROVES CLINICAL OUTCOMES IN SEPTIC PATIENTS

March 12

TELA Bio Announces Results from Retrospective Study of OviTex Reinforced BioScaffolds for Abdominal Wall Reconstruction

February 27

COST OF SEVERE SEPSIS AND SEPTIC SHOCK TREATMENT REDUCED BY OVER $14,000 PER PATIENT WITH CHEETAH MEDICAL TECHNOLOGY

February 25

NEW STUDY SHOWS IMPROVED PROTOCOL REDUCED SEPSIS MORTALITY RATE BY 85 PERCENT

February 16

Aziyo and Cook Biotech Announce Further Expansion of the Bio Envelope Franchise into Additional Markets

November 03

Zip Surgical Skin Closure Preferred over Staples During Bilateral Knee Surgery

October 31

Confidential: HighCape Partners Annual Meeting – October 2017

October 30

TELA Bio Announces Hiring of Greg Firestone as Vice President of Strategic Customer Relations

October 25

NEW STUDY DEMONSTRATES THE NEED FOR GUIDED INTRAOPERATIVE FLUIDS TO IMPROVE PATIENT OUTCOMES

October 25

Pacira Pharmaceuticals and TELA Bio Announce Equity Agreement

October 16

Confidential: Cybrexa Therapeutics Update – October 16, 2017

September 20

Recently Published Sepsis Study Supports Using Stroke Volume for Guiding Fluid Resuscitation Strategies While Reducing ICU Length of Stay by 33%

September 18

Zip Surgical Skin Closure Reduces Post-Discharge Costs, Clinic Calls and Antibiotics in First Economic Study of Device

June 06

ZipLine Medical Secures $12 Million in New Financing Led by New Investor, HighCape Partners

June 05

TELA Bio to Present Surgeon Feedback from Initial Clinical Experience with OviTex™ Reinforced BioScaffolds and Product Permeability Data at Abdominal Wall Reconstruction Conference

May 31

Aziyo Continues Building New Breed of Regenerative Medicine Company

April 04

TELA Bio Initiates BRAVO Study of OviTex™ Reinforced BioScaffolds for Hernia Repair

March 19

CHEETAH MEDICAL ANNOUNCES RESULTS OF KEY SEPSIS STUDY

March 03

TELA Bio to Participate in 16th Annual Needham Healthcare Conference

December 19

CHEETAH MEDICAL ADVANCES THE SCIENCE OF FLUID MANAGEMENT

November 11

TELA Bio Announces Settlement of Litigation with LifeCell

November 01

TELA Bio Announces OviTex™ Reinforced BioScaffolds Implanted in 100 Hernia Repair Procedures

October 10

HighCape Partners 2016 Annual Meeting

July 20

Cheetah Medical Announces Supplier Agreement with Allina Health

July 13

TELA Bio Announces Commercial Launch of OviTex™ Reinforced BioScaffolds for Ventral Hernia Repair and Abdominal Wall Reconstruction

June 15

Results from Studies of OviTex™ Reinforced BioScaffolds Presented at Abdominal Wall Reconstruction Conference

November 05

HighCape Partners and Tissue Banks International Partner to Create Cutting Edge Regenerative Medicine Company Aziyo Biologics

September 16

HighCape Partners Closes Initial $80 Million Growth Equity Fund

August 21

Cheetah Medical Secures $5 Million Investment from HighCape Partners

August 21

Cheetah Medical appoints Massachusetts General Hospital physician, Douglas M. Hansell, MD, MPH, as Chief Physician Executive

August 21

Study* Shows $3+ of Costs Can Be Avoided by Hospitals for Every $1 They Spend During Surgery by Using Noninvasive Hemodynamic Monitoring

August 08

Cheetah Medical Expands Product Line, Introduces “Starling™ SV” Noninvasive Hemodynamic Monitoring System

August 08

Cheetah Medical says its growth is outpacing global market for hemodynamic monitoring systems, expected to reach $1.1 billion by 2019, according to market research firm MarketsandMarkets

May 19

CHEETAH MEDICAL INTRODUCES STARLING SV NONINVASIVE HEMODYNAMIC MONITORING SYSTEM

March 19

CHEETAH MEDICAL SAYS ITS GROWTH IS OUTPACING GLOBAL MARKET FOR HEMODYNAMIC MONITORING SYSTEMS

January 19

DUKE UNIVERSITY STUDY SHOWS $3+ OF COSTS AVOIDED FOR EVERY $1 THEY SPEND USING NONINVASIVE HEMODYNAMIC MONITORING DURING SURGERY